Given our current stage of product development,
we currently do not have a commercialization infrastructure. If any of our diagnostic product candidates is granted marketing approval,
we intend to focus our initial commercial efforts in the United States and select European markets, which we believe represent
the largest market opportunities for us. In those markets, we expect our commercial operations to include our own specialty sales
force that will target neurologists and gerontologists, both in hospitals and in private practice. In other markets, we expect
to seek partnerships that would maximize our products’ commercial potential.
In December 2018, AC Immune and WuXi Biologics
entered into a memorandum of understanding governing the terms of a preferred partnership allowing AC Immune to leverage WuXi Biologics’
capacities and capabilities in the manufacturing and supply of traditional and innovative New Biological Entities (NBE) against
disorders of the CNS. Though this collaboration, AC Immune has priority access to WuXi Biologics’ proprietary platforms,
including the bispecific antibody platform WuXiBodyTM and WuxiUP continuous manufacturing platform. In addition, WuXi
Biologics is now a preferred partner of AC Immune for bioprocess development, as well as manufacturing for discovery, pre-clinical
and clinical supply of AC Immune’s NBE pipeline. Under the same agreement, the companies are exploring the use of AC Immune’s
platform to treat non-CNS diseases by identifying areas where AC Immune’s antibody discovery platform could generate superior
novel candidates. In addition, WuXi Vaccines, the vaccine arm of WuXi Biologics, are exploring enabling the application of AC Immune’s
We strive to protect the proprietary technology
that we believe is important to our business, including seeking and maintaining U.S. and foreign patents intended to cover our
products and compositions, their methods of use and processes for their manufacture, as well as our proprietary technology platforms,
diagnostic candidates, and any other inventions that are commercially important to the development of our business. We also rely
on trade secrets and know-how to protect aspects of our business that are not amenable to, or that we do not consider appropriate
for, patent protection.
Our success will significantly depend on
our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and
know-how related to our business, defend and enforce patents, preserve the confidentiality of our trade secrets and operate our
business without infringing any patents and other intellectual property or proprietary rights of third parties. See the section
titled “Risk Factors— Risks Related to Intellectual Property” for additional information.
As of December 31, 2018 we owned or co-owned
approximately 31 issued U.S. patents and 275 issued patents in other jurisdictions, as well as 17 pending U.S. patent applications
and 263 pending foreign patent applications. As of December 31, 2018 we licensed approximately 19 issued U.S. patents and 12 pending
U.S. patent applications, as well as 194 issued patents in other jurisdictions and 196 pending foreign patent applications.
The patent portfolios for our most advanced
product candidates as of December 31, 2018 are summarized below:
Our patent portfolio relating to crenezumab
includes patents and patent applications with claims directed to composition of matter (including claims directed to the crenezumab
antibody or a fragment thereof, a polynucleotide encoding the crenezumab antibody or a fragment thereof, a cell line used to produce
the crenezumab antibody as well as pharmaceutical compositions comprising the crenezumab antibody), claims directed to treating
certain indications using the crenezumab antibody including AD, claims directed to a method of manufacturing the crenezumab antibody,
and claims directed to diagnostic and prognostic uses of the crenezumab antibody.
Our patent portfolio relating to crenezumab
includes patents and patent applications that we own or co-own in four different patent families. As of December 31, 2018, we owned
or co-owned approximately 37 patents (not including the patents in the individual countries where the issued European patent was
validated) and 35 patent applications in 34 countries in our main patent family directed to the crenezumab antibody and methods
of using the crenezumab antibody to treat certain indications, including AD. This patent portfolio includes three issued U.S. patents
and two pending U.S. patent applications, which, if the appropriate maintenance or other governmental fees are paid, are expected
to expire in 2027, excluding any additional term for patent term adjustments or patent term extensions. This patent portfolio also
includes a PCT patent application which was filed on July 13, 2007. If the appropriate maintenance, renewal, annuity, or other
governmental fees are paid, national stage applications issuing from this PCT patent application are expected to expire in 2027,
excluding any additional term for patent term adjustments or patent term extensions, as applicable.